The competitive moat in metabolic medicine is shifting from raw weight loss to muscle preservation.
To avoid long-term strength loss and metabolic rebounds, drug developers must shift focus from total weight reduction toward maintaining lean muscle mass.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Modern clinical trials are evaluating post-bariatric weight loss quality to ensure body fat is reduced without sacrificial muscle decline.
Myostatin inhibition validating as the premier GLP-1 add-on confirms the moat shifting from pounds lost to muscle kept.
Showing exceptionally low lean muscle mass loss in Phase 3 trials highlights how next-generation drugs are competing on body composition quality rather than raw weight reduction.
Structure Therapeutics is running dedicated body composition trials to specifically assess lean muscle preservation as a critical differentiator for its oral candidate.
Established drugmakers must leverage precise MRI body composition data to defend their efficacy claims against higher-potency competitors.